{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:55Z","timestamp":1793730955127,"version":"4.6.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Human epidermal growth factor receptor 2 (HER2)-positive cholangiocarcinoma is a rare disease with a low incidence and high degree of malignancy. Trastuzumab deruxtecan (T-DXd) has been approved for the treatment of HER2-positive breast and gastric cancer. However, it is still in the initial exploration period for HER2-positive cholangiocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 57-year-old Han Chinese male patient with recurrent metastatic cholangiocarcinoma who was tested for HER2 expression in surgical specimens in the absence of reliable drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Postoperative pathological examination confirmed a diagnosis of moderately to poorly differentiated adenocarcinoma of the common bile duct.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Our case revealed HER2 amplification and effectively received T-DXd as backline therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After approximately 4 months without disease progression, the patient experienced an increase in plasma tumor markers; however, he regained disease control after receiving T-DXd in combination with lenvatinib with a favorable physical status and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Reexamination of tumor tissue samples to identify target mutations is necessary for backline treatment of cholangiocarcinoma. T-DXd is effective in the treatment of HER2 amplification cholangiocarcinoma and is relatively well tolerated after multiple lines of therapy. The combination of multi-target tyrosinase inhibitors is a possible strategy for overcoming resistance in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044094","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:01:23Z","timestamp":1756494083000},"page":"e44094","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Advanced cholangiocarcinoma with human epidermal growth factor receptor 2 (HER2) amplification treated with Trastuzumab deruxtecan (T-DXd): A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Xiaohui","family":"Bao","sequence":"first","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhou","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0130-2240","authenticated-orcid":false,"given":"Ni","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"155","DOI":"10.17998\/jlc.2024.08.07","article-title":"New systemic treatment options for advanced cholangiocarcinoma.","volume":"24","author":"Zanuso","year":"2024","journal-title":"J Liver Cancer"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the european network for the study of cholangiocarcinoma (ENS-CCA).","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/cells12162098","article-title":"Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis.","volume":"12","author":"Frega","year":"2023","journal-title":"Cells"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/ijms25021064","article-title":"Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers.","volume":"25","author":"Rubin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11523-022-00942-6","article-title":"Optimizing patient pathways in advanced biliary tract cancers: recent advances and a french perspective.","volume":"18","author":"Neuzillet","year":"2023","journal-title":"Target Oncol"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"R11-20260406","first-page":"582","article-title":"Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma.","volume":"49","author":"Jung","year":"2017","journal-title":"Pathology (Phila)"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"71","DOI":"10.32074\/1591-951X-859","article-title":"FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice.","volume":"115","author":"Angerilli","year":"2023","journal-title":"Pathologica"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"102789","DOI":"10.1016\/j.ctrv.2024.102789","article-title":"HER-2 directed therapies across gastrointestinal tract cancers \u2013 a new frontier.","volume":"129","author":"Jones","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2\u2013expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial.","volume":"42","author":"Ohba","year":"2024","journal-title":"J Clin Oncol"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17_suppl","key":"R17-20260406","doi-asserted-by":"crossref","first-page":"LBA3000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/jcpt.13777","article-title":"Safety of trastuzumab deruxtecan: a meta\u2010analysis and pharmacovigilance study.","volume":"47","author":"Guo","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates.","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody\u2013drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:00:21Z","timestamp":1775455221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":20,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044094","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2025-05-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}